HUTCHMED (CHINA) LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 346 GBX | -1.14% |
|
+12.34% | +22.26% |
| 11:55am | Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer | MT |
| 05:11am | Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3% | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HUTCHMED (CHINA) LIMITED | Other Pharmaceuticals | -1.14% | +12.34% | +22.26% | +52.42% | -4.55% | 3.75B |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- HCM Stock
- Charts HUTCHMED (China) Limited
- Comparison Chart